Thermo Fisher Scientific has entered into a definitive agreement to purchase One Lambda, a provider of transplant diagnostics services, for $925m in cash.
One Lambda offers antibody detection assays that are used by transplant centers for tissue typing to detect the presence of antibodies that can lead to transplant rejection as well as to determine the compatibility of donors and recipients pre-transplant.
Thermo Fisher president and chief executive officer Marc N. Casper said with technology platform, high margin profile and good growth prospects, One Lambda's business is perfectly aligned with the company's specialty in vitro diagnostics strategy.
"We are also pleased to announce that we will collaborate with Dr. Terasaki and the Terasaki Foundation Laboratory, which continues to support groundbreaking research in preventing post-transplant rejection," Casper added.
One Lambda co-founder president and chief executive officer George M. Ayoub said, "I believe that, together, we will increase the use of human leukocyte antigen (HLA) typing and antibody detection to accelerate growth and improve the success rate of transplantation."
The transaction, which is subject to post-closing adjustment, is expected to be completed in the fourth quarter of 2012.
The transaction also expects to be immediately accretive upon close and add $0.09 to $0.11 to Thermo Fisher's 2013 adjusted earnings per share.
